BioSyent (CVE:RX) Stock Passes Above 50 Day Moving Average – Time to Sell?

Shares of BioSyent Inc. (CVE:RX) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$11.35 and traded as high as C$11.43. BioSyent shares last traded at C$11.43, with a volume of 100 shares changing hands.

BioSyent Stock Performance

The stock has a market cap of C$132.47 million, a price-to-earnings ratio of 19.05 and a beta of 0.93. The firm’s 50-day moving average price is C$11.35 and its two-hundred day moving average price is C$10.80. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13.

Insider Buying and Selling at BioSyent

In other BioSyent news, insider FAX Capital Corp. sold 112,400 shares of BioSyent stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total transaction of C$1,267,557.28. Also, Senior Officer Robert Joseph March sold 4,775 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. Insiders have sold 349,144 shares of company stock worth $3,903,370 in the last ninety days. 33.65% of the stock is owned by insiders.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.